BR100 Increased By (1.82%)
BR30 Increased By (1.76%)
KSE100 Increased By (2.08%)
KSE30 Increased By (2.29%)
BECO 5.39 No Change ▼ 0.00 (0%)
BML 57.46 Increased By ▲ 0.98 (1.74%)
BOP 36.31 Increased By ▲ 1.22 (3.48%)
CNERGY 8.21 Increased By ▲ 0.04 (0.49%)
DCL 11.83 Increased By ▲ 0.39 (3.41%)
FCCL 59.28 Increased By ▲ 1.73 (3.01%)
FCSC 5.01 Increased By ▲ 0.01 (0.2%)
FFL 17.85 Decreased By ▼ -0.03 (-0.17%)
FNEL 1.26 Increased By ▲ 0.01 (0.8%)
HUMNL 11.50 Increased By ▲ 0.33 (2.95%)
KEL 8.33 Decreased By ▼ -0.21 (-2.46%)
KOSM 6.63 Decreased By ▼ -0.10 (-1.49%)
MLCF 107.43 Increased By ▲ 0.52 (0.49%)
NBP 205.01 Increased By ▲ 6.51 (3.28%)
PACE 11.10 Increased By ▲ 0.03 (0.27%)
PAEL 45.42 Decreased By ▼ -0.03 (-0.07%)
PIAHCLA 31.76 Increased By ▲ 0.33 (1.05%)
PIBTL 18.85 Decreased By ▼ -0.23 (-1.21%)
PPL 243.74 Increased By ▲ 1.12 (0.46%)
PRL 36.24 Increased By ▲ 0.57 (1.6%)
PTC 72.07 Increased By ▲ 6.55 (10%)
SEARL 94.58 Increased By ▲ 0.04 (0.04%)
SSGC 31.85 Decreased By ▼ -0.23 (-0.72%)
TELE 9.02 Increased By ▲ 0.15 (1.69%)
THCCL 68.47 Increased By ▲ 2.81 (4.28%)
TPLP 10.72 Decreased By ▼ -0.01 (-0.09%)
TREET 25.89 Increased By ▲ 0.78 (3.11%)
TRG 64.31 Increased By ▲ 0.64 (1.01%)
WAVES 10.91 Increased By ▲ 0.21 (1.96%)
WTL 1.29 Increased By ▲ 0.04 (3.2%)

The Drug Regulatory Authority of Pakistan (DRAP)’s first drug testing laboratory has secured prequalification from the World Health Organization (WHO) amid efforts of the Special Investment Facilitation Council (SIFC), reflecting growing global confidence in Pakistan’s regulatory systems.

According to a statement on Thursday, SIFC ensured coordination at the domestic level while also engaging effectively with international stakeholders to make this achievement possible.

The state-of-the-art drug testing laboratory will be established in Karachi and will operate under the administration of DRAP.

DRAP urged to follow full process before declaring medicines substandard

As per the statement, multiple domestic and international challenges were successfully addressed throughout the process by SIFC’s.

The WHO accreditation is expected to significantly enhance the global credibility of Pakistan’s pharmaceutical quality and regulatory framework, leading to a notable increase in pharmaceutical exports. It will also strengthen investor confidence in Pakistan’s pharmaceutical manufacturing sector.

Furthermore, this development will reduce Pakistan’s reliance on foreign laboratories by enabling high-quality testing capabilities within the country.

The council was of the view that this achievement underscores Pakistan’s continued progress towards regulatory modernisation and institutional strengthening, with SIFC playing a pivotal role in advancing these efforts.

Comments

200 characters remaining